Pay in 4 interest-free payments of $5.11 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
DESCRIPTION TABLE OF CONTENTS METHODOLOGY DOWNLOAD PDF Biosimilars Market by Drug Class (mAbs (Adalimumab, Infliximab, Rituximab, Trastuzumab), GCSF, Insulin, Anticoagulant, rhGH, Teriparatide, GLP-1), Indication (Oncology, Autoimmune, Diabetes, Obesity), Competitive Landscape, Region - Global Forecast to 2035 USD 72.29 BN MARKET SIZE, 2035 BIOSIMILARS MARKET SIZE, SHARE & GROWTH SNAPSHOT Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis The global biosimilars market is projected to grow from USD 35.04 billion in 2025 to USD 72.29 billion by 2035, at a CAGR of 7.5% during the forecast period
Frequently Asked Questions What is the standard GHK-Cu injection dosage
Brand names : Mounjaro (for diabetes), Zepbound (for weight loss) Quick Fact : Both medications are injected once weekly and are approved for use in adults with obesity or overweight individuals with at least one weight-related health condition
GIPs other functions include fat metabolism and promoting beta cell proliferation [5]
US$ 23.63
US$ 25.20
US$ 28.10
US$ 22.91
)
